

EMA/314185/2016

European Medicines Agency decision

P/0156/2016

of 15 June 2016

on the acceptance of a modification of an agreed paediatric investigation plan for clostridium Botulinum neurotoxin type A (150 kD), free of complexing proteins (Xeomin, Bocouture) (EMEA-001039-PIP02-12-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0156/2016

of 15 June 2016

on the acceptance of a modification of an agreed paediatric investigation plan for clostridium Botulinum neurotoxin type A (150 kD), free of complexing proteins (Xeomin, Bocouture) (EMEA-001039-PIP02-12-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0143/2013 issued on 3 July 2013, and the decision P/0005/2016 issued on 25 January 2016,

Having regard to the application submitted by Merz Pharmaceuticals GmbH on 5 February 2016 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 29 April 2016, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the waiver.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for clostridium Botulinum neurotoxin type A (150 kD), free of complexing proteins (Xeomin, Bocouture), powder for solution for injection, solution for injection in pre-filled syringe, intraparenchymal use, including changes to the waiver, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Merz Pharmaceuticals GmbH, Eckenheimer Landstr. 100, 60318 - Frankfurt (Main), Germany.

Done at London, 15 June 2016

For the European Medicines Agency
Zaïde Frias
Head of Division
Human Medicines Research and Development Support
(Signature on file)

EMA/PDCO/103576/2016

London, 29 April 2016

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001039-PIP02-12-M02

Scope of the application

Active substance(s):

Clostridium Botulinum neurotoxin type A (150 kD), free of complexing proteins

Invented name:

Xeomin

Bocouture

Condition(s):

Treatment of sialorrhoea

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Powder for solution for injection

Solution for injection in pre-filled syringe

Route(s) of administration:

Intraparenchymal use

Name / corporate name of the PIP applicant:

Merz Pharmaceuticals GmbH

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Merz Pharmaceuticals GmbH submitted to the European Medicines Agency on 05 February 2016 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0143/2013 issued on 3 July 2013, and the decision P/0005/2016 issued on 25 January 2016.

The application for modification proposed changes to the agreed paediatric investigation plan and to the waiver.

The procedure started on 1 March 2016.

Scope of the modification

A new pharmaceutical form has been added and the scope of the waiver has been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree to changes to the paediatric investigation plan and to the waiver in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of sialorrhoea

The waiver applies to:

- the paediatric population from birth to less than 2 years;
- for powder for solution for injection, solution for injection in pre-filled syringe, intraparenchymal use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition:

Treatment of sialorrhoea

2.1.1. Indication(s) targeted by the PIP

Treatment of chronic sialorrhoea associated with neurologic conditions and/or intellectual disability

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Powder for solution for injection, solution for injection in pre-filled syringe

2.1.4. Measures

Area	Number of measures	Description
Quality	0	Not applicable.
Non-clinical	0	Not applicable.
Clinical	1	Measure 1: Double-blind, randomised, multi-centre, placebo controlled trial to evaluate safety and efficacy of Clostridium Botulinum neurotoxin type A (150 kD) in children from 2years to less than 18 years of age with chronic sialorrhoea associated with neurologic conditions and/or intellectual disability, with an open-label extension study to evaluate safety.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No.
Date of completion of the paediatric investigation plan:	By April 2019.
Deferral for one or more measures contained in the paediatric investigation plan:	Yes.

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of muscle spasticity

Authorised indications (Xeomin):

- treatment of post-stroke spasticity of the upper limb presenting with flexed wrist and clenched fist in adult patient.

2. Treatment of dystonia

Authorised indications (Xeomin):

- treatment of cervical dystonia of a predominantly rotational form (spasmodic torticollis) in adult patients;
- treatment of blepharospasmus in adult patients.

3. Treatment of muscle-induced wrinkles

Authorised indications (Bocouture):

- treatment of upper facial lines in adults below 65 years when the severity of these lines has an important psychological impact for the patient:
 - moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar frown lines) and/or
 - moderate to severe lateral periorbital lines seen at maximum smile (crow's feet lines) and/or
 - moderate to severe horizontal forehead lines seen at maximum contraction.

Authorised pharmaceutical form(s):

Powder for solution for injection

Authorised route(s) of administration:

Intramuscular use